<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="aa6213f5-e549-4e42-a795-b791de8353b7"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use CORPHEDRA<sup>TM</sup> safely and effectively. See full prescribing information for CORPHEDRA.</content>
      <br/>
      <br/>
      <content styleCode="bold">CORPHEDRA (ephedrine sulfate injection, USP) for intravenous use </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2016</content>
   </title>
   <effectiveTime value="20181017"/>
   <setId root="98531820-a85c-4ee7-9338-2be264219afe"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="092733690" root="1.3.6.1.4.1.519.1"/>
            <name>Par Pharmaceutical, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="85aa1c23-8d02-44c4-8976-36f0b1cd0c56"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20210814"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="42023-196" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Corphedra</name>
                        <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ephedrine Sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="U6X61U5ZEG" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EPHEDRINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="GN83C131XS" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EPHEDRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="42023-196-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" displayName="VIAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="25"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="42023-196-25" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20170216"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208943" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170216"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="42023-233" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Corphedra</name>
                        <formCode code="C42945" displayName="INJECTION, SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ephedrine sulfate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="mL" value="10"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="U6X61U5ZEG" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EPHEDRINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="GN83C131XS" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>EPHEDRINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="42023-233-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" displayName="VIAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190118"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208943" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190118"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_87830e83-2c8e-4576-9b1a-513431ac82a4">
               <id root="650b3267-3913-4de7-8130-450f126d87fc"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>CORPHEDRA is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.</paragraph>
               </text>
               <effectiveTime value="20170127"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>CORPHEDRA is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. <linkHtml href="#LINK_1a6f4178-94d7-43cf-a243-875c3966f480">(1)</linkHtml> </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8e55e584-0e01-429c-8fa0-67521f68a2f1">
               <id root="332ad623-d5f2-452d-b3b3-a4d6affce7ca"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20170127"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Treatment of hypotension developing during anesthesia: Bolus intravenous injection: 5 to 10 mg as needed, not to exceed 50 mg.  Dilute before use.  See Full Prescribing Information for instructions on administration and preparation for injection. <linkHtml href="#LINK_38e973d4-e1e3-4cf2-b682-251097990ee2">(2)</linkHtml> </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_85f1bdc6-6cfc-48e6-8863-93b10f3ffc75">
                     <id root="ceb4a236-ef2d-44bb-8615-73ed8098ac08"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Dosage and
Administration Instructions

<br/>
                     </title>
                     <text>
                        <paragraph>CORPHEDRA must be diluted before administration to achieve the desired concentration as an intravenous bolus or intravenous infusion.  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the solution is colored or cloudy, or if it contains particulate matter.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d55de3a0-e2ac-4ffe-b6f3-bbf977ac615a">
                     <id root="d9435157-e1f3-453c-b93d-0d4ae71f86df"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosing
for the Treatment of Clinically Important Hypotension in the Setting of
Anesthesia

<br/>
                     </title>
                     <text>
                        <paragraph>The recommended dosage for the treatment of clinically important hypotension in the setting of anesthesia is an initial dose of 5 to 10 mg administered by intravenous bolus. Administer additional boluses as needed, not to exceed a total dosage of 50 mg.</paragraph>
                        <paragraph>Adjust dosage according to the blood pressure goal (i.e., titrate to effect).</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2fb2a6e6-6bc6-42d0-ae43-f7232614889a">
                     <id root="eaf03270-59fa-43f0-bc39-5cc328eda0dc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Preparation of a 5 mg/mL Solution for Bolus
Intravenous Administration

<br/>
                     </title>
                     <text>
                        <paragraph>For bolus intravenous administration, prepare a solution containing a final concentration of 5 mg/mL of ephedrine sulfate injection.</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Withdraw 50 mg (1 mL of 50 mg/mL) of ephedrine sulfate injection and dilute with 9 mL of 5% Dextrose Injection or Sodium Chloride Injection.</item>
                        </list>
                        <list listType="unordered" styleCode="Disk">
                           <item>Withdraw an appropriate dose of the 5 mg/mL solution prior to bolus intravenous administration.</item>
                        </list>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0546d6c9-f9bb-4fc9-bc50-4c98fa61c592">
               <id root="283f2579-1a40-475d-9e8d-a378856ad2ca"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 50 mg/mL ephedrine sulfate, equivalent to 38 mg ephedrine base.</paragraph>
               </text>
               <effectiveTime value="20181017"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 50 mg/mL ephedrine sulfate <linkHtml href="#LINK_e1f71715-c1f6-44f3-b581-adb1426b4831">(3)</linkHtml> </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_fbdf7c22-c16e-4e42-90d9-18e1f666a1d8">
               <id root="b9e71641-6739-4e04-9460-edc49e6507f2"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20170127"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None <linkHtml href="#LINK_69a67555-6e7a-4562-b4f1-537f19bf6e8f">(4)</linkHtml> </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_5b4f988b-ad18-4507-9394-bd0b45858c0b">
               <id root="b210bc6e-968a-447f-a8d5-b0e16563e39b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20170127"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>•       <content styleCode="underline">Pr</content>
                           <content styleCode="underline">e</content>
                           <content styleCode="underline">ssor Effect with Concomitant Oxytocic Drugs</content>: Pressor effect of sympathomimetic pressor amines is potentiated <linkHtml href="#LINK_6e602df1-f48a-4ffb-b678-fec3185f9ae0">(5.1)</linkHtml> </paragraph>
                        <paragraph>•       <content styleCode="underline">T</content>
                           <content styleCode="underline">ach</content>
                           <content styleCode="underline">y</content>
                           <content styleCode="underline">ph</content>
                           <content styleCode="underline">y</content>
                           <content styleCode="underline">l</content>
                           <content styleCode="underline">a</content>
                           <content styleCode="underline">x</content>
                           <content styleCode="underline">i</content>
                           <content styleCode="underline">s and Tolerance</content>: Repeated administration of ephedrine may cause tachyphylaxis <linkHtml href="#LINK_ab684b0f-ef78-463a-a809-53596f4fe995">(5.2)</linkHtml> </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_6e602df1-f48a-4ffb-b678-fec3185f9ae0">
                     <id root="667192c9-6031-4373-86aa-72fb59d6cf80"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Pressor Effect with
Concomitant Oxytocic Drugs

<br/>
                     </title>
                     <text>
                        <paragraph>Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine) [<content styleCode="italics">
                              <linkHtml href="#LINK_223f5dda-8854-4b08-8818-b2186a22090c">see Drug Interactions (7)</linkHtml>
                           </content>]. Some of these patients experienced a stroke. Carefully monitor the blood pressure of individuals who have received both ephedrine and an oxytocic.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ab684b0f-ef78-463a-a809-53596f4fe995">
                     <id root="ad5bf4b2-9546-4221-a4a5-d4d512539d2c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Tolerance and Tachyphylaxis

<br/>
                     </title>
                     <text>
                        <paragraph>Data indicate that repeated administration of ephedrine can result in tachyphylaxis. Clinicians treating anesthesia-induced hypotension with CORPHEDRA should be aware of the possibility of tachyphylaxis and should be prepared with an alternative pressor to mitigate unacceptable responsiveness.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7203f877-b32c-404b-884a-accc84f61327">
                     <id root="698b193a-f51f-45fa-9ad2-e8ade6c605c7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Risk of
Hypertension When Used Prophylactically

<br/>
                     </title>
                     <text>
                        <paragraph>When used to prevent hypotension, ephedrine has been associated with an increased incidence of hypertension compared with when ephedrine is used to treat hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5928e765-5c28-429b-9232-a8c2bfe229ed">
               <id root="8d763846-6e6e-4068-8037-b8e262e24ef5"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions associated with the use of ephedrine sulfate were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Gastrointestinal disorders</content>: Nausea, vomiting</paragraph>
                  <paragraph>
                     <content styleCode="underline">C</content>
                     <content styleCode="underline">ardiac disorders</content>: Tachycardia, palpitations (thumping heart), reactive hypertension, bradycardia, ventricular ectopics, R-R variability</paragraph>
                  <paragraph>
                     <content styleCode="underline">N</content>
                     <content styleCode="underline">e</content>
                     <content styleCode="underline">rvous system disorders</content>: Dizziness</paragraph>
                  <paragraph>
                     <content styleCode="underline">Psychiatric disorders</content>: Restlessness</paragraph>
                  <paragraph>
                     <content styleCode="bold">For medical advice about adverse reactions, contact your medical professional. </content>To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical at 1-800-828-9393 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</paragraph>
               </text>
               <effectiveTime value="20170127"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions during treatment: nausea, vomiting, and tachycardia.<linkHtml href="#LINK_675bbff7-5b49-4045-b686-aa2dff5fcb57">(6)</linkHtml> </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical at 1-800-828-9393 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_a9f48fb2-b731-494a-8f27-830e4f3be392">
               <id root="a9039bbb-63cd-43b8-979f-c86ad77467ab"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <table border="1" cellspacing="0" cellpadding="0">
                     <col width="6.65in"/>
                     <col/>
                     <tbody>
                        <tr>
                           <td colspan="2">
                              <paragraph>
                                 <content styleCode="bold">I</content>
                                 <content styleCode="bold">nteractions that Augment the Pressor Effect</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">Oxytocin and oxytocic drugs</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">C</content>
                                 <content styleCode="italics">linical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Serious postpartum hypertension has been described in patients who received both a vasopressor (i.e., methoxamine, phenylephrine, ephedrine) and an oxytocic (i.e., methylergonovine, ergonovine). Some of these patients experienced a stroke.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">I</content>
                                 <content styleCode="italics">ntervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Carefully monitor the blood pressure of individuals who have received both ephedrine and an oxytocic.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">Clonidine, propofol, monoamine oxidase inhibitors (MAOIs), atropine</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">C</content>
                                 <content styleCode="italics">linical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>These drugs augment the pressor effect of ephedrine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">I</content>
                                 <content styleCode="italics">ntervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">I</content>
                                 <content styleCode="bold">nteractions that Antagonize the Pressor Effect</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">C</content>
                                 <content styleCode="italics">linical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>These drugs antagonize the pressor effect of ephedrine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">I</content>
                                 <content styleCode="italics">ntervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Carefully monitor the blood pressure of individuals who have received both ephedrine and any of these drugs.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">Examples:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>α-adrenergic antagonists, β-adrenergic receptor antagonists,</paragraph>
                              <paragraph>reserpine, quinidine, mephentermine</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">Other Drug Interactions</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">G</content>
                                 <content styleCode="bold">u</content>
                                 <content styleCode="bold">anethidine</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">C</content>
                                 <content styleCode="italics">linical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Ephedrine may inhibit the neuron blockage produced by</paragraph>
                              <paragraph>guanethidine, resulting in loss of antihypertensive effectiveness.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">I</content>
                                 <content styleCode="italics">ntervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Clinician should monitor patient for blood pressor response and adjust the dosage or choice of pressor accordingly.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">Rocuronium</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">C</content>
                                 <content styleCode="italics">linical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">I</content>
                                 <content styleCode="italics">ntervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Be aware of this potential interaction. No treatment or other interventions are needed.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">Ep</content>
                                 <content styleCode="bold">idural anesthesia</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">C</content>
                                 <content styleCode="italics">linical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Ephedrine may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">I</content>
                                 <content styleCode="italics">ntervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Monitor and treat the patient according to clinical practice.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">Th</content>
                                 <content styleCode="bold">e</content>
                                 <content styleCode="bold">ophylline</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">C</content>
                                 <content styleCode="italics">linical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Concomitant use of ephedrine may increase the frequency of nausea, nervousness, and insomnia.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">I</content>
                                 <content styleCode="italics">ntervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Monitor patient for worsening symptoms and manage symptoms according to clinical practice.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="bold">Cardiac glycosides</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">C</content>
                                 <content styleCode="italics">linical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Giving ephedrine with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">
                              <paragraph>
                                 <content styleCode="italics">I</content>
                                 <content styleCode="italics">ntervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Toprule Lrule">
                              <paragraph>Carefully monitor patients on cardiac glycosides who are also administered ephedrine.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <br/>
               </text>
               <effectiveTime value="20170127"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>•       <content styleCode="underline">I</content>
                           <content styleCode="underline">nt</content>
                           <content styleCode="underline">e</content>
                           <content styleCode="underline">r</content>
                           <content styleCode="underline">a</content>
                           <content styleCode="underline">ctio</content>
                           <content styleCode="underline">n</content>
                           <content styleCode="underline">s </content>
                           <content styleCode="underline">t</content>
                           <content styleCode="underline">ha</content>
                           <content styleCode="underline">t Augment the Pressor Effect</content>: clonidine, oxytocin and oxytocic drugs, propofol, monoamine oxidase inhibitors (MAOIs), and atropine. Monitor blood pressure. <linkHtml href="#LINK_223f5dda-8854-4b08-8818-b2186a22090c">(7)</linkHtml> </paragraph>
                        <paragraph>•       <content styleCode="underline">I</content>
                           <content styleCode="underline">nt</content>
                           <content styleCode="underline">e</content>
                           <content styleCode="underline">r</content>
                           <content styleCode="underline">acti</content>
                           <content styleCode="underline">o</content>
                           <content styleCode="underline">n</content>
                           <content styleCode="underline">s that Antagonize the Pressor Effect</content>: Antagonistic effects with α-adrenergic antagonists, β-adrenergic antagonists, reserpine, quinidine, mephentermine. Monitor blood pressure. <linkHtml href="#LINK_223f5dda-8854-4b08-8818-b2186a22090c">(7)</linkHtml> </paragraph>
                        <paragraph>•       <content styleCode="underline">G</content>
                           <content styleCode="underline">uan</content>
                           <content styleCode="underline">e</content>
                           <content styleCode="underline">t</content>
                           <content styleCode="underline">h</content>
                           <content styleCode="underline">i</content>
                           <content styleCode="underline">d</content>
                           <content styleCode="underline">in</content>
                           <content styleCode="underline">e</content>: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. Monitor blood pressure and adjust the dosage of pressor accordingly. <linkHtml href="#LINK_223f5dda-8854-4b08-8818-b2186a22090c">(7)</linkHtml> </paragraph>
                        <paragraph>•       <content styleCode="underline">R</content>
                           <content styleCode="underline">o</content>
                           <content styleCode="underline">cu</content>
                           <content styleCode="underline">roni</content>
                           <content styleCode="underline">u</content>
                           <content styleCode="underline">m</content>: Ephedrine may reduce the onset time of neuromuscular blockade when used for intubation with rocuronium if administered simultaneously with anesthetic induction. Be aware of this potential interaction. No treatment or other interventions are needed. <linkHtml href="#LINK_223f5dda-8854-4b08-8818-b2186a22090c">(7)</linkHtml> </paragraph>
                        <paragraph>•       <content styleCode="underline">Epidural anesthesia</content>: Ephedrine may decrease the efficacy of epidural blockade by hastening the regression of sensory analgesia. Monitor and treat the patient according to clinical practice. <linkHtml href="#LINK_223f5dda-8854-4b08-8818-b2186a22090c">(7)</linkHtml> </paragraph>
                        <paragraph>•       <content styleCode="underline">T</content>
                           <content styleCode="underline">h</content>
                           <content styleCode="underline">e</content>
                           <content styleCode="underline">o</content>
                           <content styleCode="underline">ph</content>
                           <content styleCode="underline">yll</content>
                           <content styleCode="underline">in</content>
                           <content styleCode="underline">e</content>: Concomitant use of ephedrine may increase the frequency of nausea, nervousness, and insomnia. Monitor patient for worsening symptoms and manage symptoms according to clinical practice. <linkHtml href="#LINK_223f5dda-8854-4b08-8818-b2186a22090c">(7)</linkHtml> </paragraph>
                        <paragraph>•       <content styleCode="underline">Ca</content>
                           <content styleCode="underline">rd</content>
                           <content styleCode="underline">i</content>
                           <content styleCode="underline">a</content>
                           <content styleCode="underline">c glycosides</content>: Giving ephedrine with a cardiac glycoside, such as digitalis, may increase the possibility of arrhythmias. Carefully monitor patients on cardiac glycosides who are also administered ephedrine. <linkHtml href="#LINK_223f5dda-8854-4b08-8818-b2186a22090c">(7)</linkHtml> </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_620c01ec-d194-46f0-b8c7-70fd7f92c264">
               <id root="111363e9-0eae-4921-86bb-18dfd00c10f3"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20170127"/>
               <component>
                  <section ID="LINK_9a6bb37c-666f-46fb-be19-aa7e819e1557">
                     <id root="bf386550-3432-475f-a649-1bcc0da4a3a4"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">R</content>
                           <content styleCode="underline">isk Summary</content>
                        </paragraph>
                        <paragraph>Limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. However, there are clinical considerations <content styleCode="italics">[<linkHtml href="#LINK_e475f237-3e80-443e-8922-4a4c39273af8">see Clinical Considerations</linkHtml>]</content>. Animal reproduction studies have not been conducted with ephedrine sulfate.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.  All pregnancies have a background risk of birth defect, loss, or</paragraph>
                        <paragraph>other adverse outcomes.  In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">C</content>
                           <content styleCode="underline">linical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal adverse reactions</content>
                        </paragraph>
                        <paragraph>Cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. These reports describe umbilical artery pH of ≤7.2 at the time of delivery <content styleCode="italics">[<linkHtml href="#LINK_969fd8b8-d313-46fb-9ba5-364abcc95b56">see Clinical Pharmacology 12.3</linkHtml>]</content>. Monitoring of the newborn for signs and symptoms of metabolic acidosis may be required. Monitoring of infant’s acid-base status is warranted to ensure that an episode of acidosis is acute and reversible<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b793dd1f-8b40-4138-ad6e-0bf451d14a02">
                     <id root="729d39f2-d4d6-4800-af59-eacd7b91b9b5"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">R</content>
                           <content styleCode="underline">isk Summary</content>
                        </paragraph>
                        <paragraph>Limited published literature reports that ephedrine is present in human milk. However, no information is available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for CORPHEDRA  and any potential adverse effects on the breastfed child from CORPHEDRA  or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ca47e416-5831-4010-9d2d-8974b5f3daf3">
                     <id root="ce592973-ed0b-46df-8f48-a117aee59af3"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ec14c087-21d2-4394-ab86-f7f58fe8a02d">
                     <id root="22f5acd5-7c1a-4159-b6f1-d4578ceed2a3"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of ephedrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</paragraph>
                        <paragraph>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_de469294-36c5-481d-8f41-3889f5f6628f">
                     <id root="8300f33c-9814-446a-b046-2ff490142326"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Ephedrine and its metabolite are excreted in urine. In patients with renal impairment, excretion of ephedrine is likely to be affected with a corresponding increase in elimination half-life, which will lead to slow elimination of ephedrine and consequently prolonged pharmacological effect and potentially adverse reactions. Monitor patients with renal impairment carefully after the initial bolus dose for adverse events.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d0a8769d-e081-44f1-a5a8-d06f9122ab72">
               <id root="21ebe33c-f269-497c-b0c0-d2ef141aa422"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Overdose of ephedrine can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.</paragraph>
               </text>
               <effectiveTime value="20170127"/>
            </section>
         </component>
         <component>
            <section ID="LINK_4e30b721-fbd5-4edf-a424-bd7aea0fe161">
               <id root="1c8ed0b0-cef6-4c26-930b-232dc649f64d"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Ephedrine sulfate is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent. CORPHEDRA (ephedrine sulfate injection) is a clear, colorless, sterile solution for intravenous injection. The 1 mL solution contains ephedrine sulfate 50 mg in water for injection as a single-dose product.  The 10 mL solution contains ephedrine sulfate 500 mg and phenol (a preservative) in water for injection as a multi-dose product (50 mg/mL).  The pH range is 4.5 to 7.0.  The drug product must be diluted before intravenous administration. The chemical name of ephedrine sulfate is (1R,2S)-(-)-2-methylamine-1-phenylpropan-1-ol sulfate (2:1) (salt). Its molecular weight is 428.54. </paragraph>
                  <paragraph>The structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1">
                     <caption>Image 1</caption>
                  </renderMultiMedia>
                  <paragraph>Ephedrine sulfate darkens on exposure to light.  It is freely soluble in water and ethanol, very slightly soluble in chloroform, and practically insoluble in ether.  </paragraph>
               </text>
               <effectiveTime value="20181017"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_81878798-4531-4611-bfcc-5feced60c400">
               <id root="8ac0222d-151e-4df7-9499-53d2cb83dde9"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20170127"/>
               <component>
                  <section ID="LINK_6902b24b-39fc-495f-ab48-c4ef4fa86a74">
                     <id root="46bd8b66-d4f9-48d0-877c-ded6c5814bee"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Ephedrine sulfate is a sympathomimetic amine that directly acts as an agonist at α- and ß­ adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic stimulation is caused by norepinephrine release from sympathetic nerves.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_51d0c108-8072-4185-a6ad-bbc1085416f0">
                     <id root="c18a9c36-f36d-4543-a82c-283d7fc71456"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Ephedrine stimulates heart rate and cardiac output and variably increases peripheral resistance; as a result, ephedrine usually increases blood pressure. Stimulation of the α-adrenergic receptors of smooth muscle cells in the bladder base may increase the resistance to the outflow of urine. Activation of ß-adrenergic receptors in the lungs promotes bronchodilation.</paragraph>
                        <paragraph>The overall cardiovascular effect from ephedrine is the result of a balance among α-1 adrenoceptor-mediated vasoconstriction, ß-2 adrenoceptor-mediated vasoconstriction, and ß-2 adrenoceptor-mediated vasodilatation. Stimulation of the ß-1 adrenoceptors results in positive inotrope and chronotrope action.</paragraph>
                        <paragraph>Tachyphylaxis to the pressor effects of ephedrine may occur with repeated administration <content styleCode="italics">[<linkHtml href="#LINK_7203f877-b32c-404b-884a-accc84f61327">see Warnings and Precautions 5.3</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0815c71e-1e33-4316-a18d-bf23d1aaeb7b">
                     <id root="ae4778a6-936a-43d8-82da-c1119dbe2093"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Publications studying pharmacokinetics of oral administration of (-)-ephedrine support that (-)­-ephedrine is metabolized into norephedrine. However, the metabolism pathway is unknown. Both the parent drug and the metabolite are excreted in urine. Limited data after IV administration of ephedrine support similar observations of urinary excretion of drug and metabolite. The plasma elimination half-life of ephedrine following oral administration was about 6 hours.</paragraph>
                        <paragraph>Ephedrine crosses the placental barrier <content styleCode="italics">[<linkHtml href="#LINK_e475f237-3e80-443e-8922-4a4c39273af8">see Use in Specific Populations 8.1</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c2572e58-edad-4537-8d10-d7604ce8cfa5">
               <id root="bc6aea9e-9417-4de1-aa58-3e559a1043a6"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20170127"/>
               <component>
                  <section ID="LINK_b5001311-08ec-4183-bf6c-60649bfdf367">
                     <id root="06da50a4-1067-46e9-8e79-b44573f68e61"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">C</content>
                           <content styleCode="underline">arc</content>
                           <content styleCode="underline">inogenesis</content>:  Two-year feeding studies in rats and mice conducted under the National Toxicology Program (NTP) demonstrated no evidence of carcinogenic potential with ephedrine sulfate at doses up to 10 mg/kg/day and 27 mg/kg/day (approximately 2 times and 3 times the maximum human recommended dose on a mg/m<sup>2</sup> basis, respectively).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>:  Ephedrine sulfate tested negative in the in vitro bacterial reverse mutation assay, the in vitro mouse lymphoma assay, the in vitro sister chromatid exchange, and the in vitro chromosomal aberration assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">I</content>
                           <content styleCode="underline">mpairment of Fertility</content>:  Studies to evaluate the effect of ephedrine on fertility have not been conducted.</paragraph>
                     </text>
                     <effectiveTime value="20170127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_764d6076-c8f5-4477-bc21-22b4415393e1">
               <id root="d762656f-3aaa-4f19-9d35-4793e698eb70"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The evidence for the efficacy of ephedrine injection is derived from the published literature. Increases in blood pressure following administration of ephedrine were observed in 14 studies, including 9 where ephedrine was used in pregnant women undergoing neuraxial anesthesia during Cesarean delivery, 1 study in non-obstetric surgery under neuraxial anesthesia, and 4 studies in patients undergoing surgery under general anesthesia. Ephedrine has been shown to raise systolic and mean blood pressure when administered as a bolus dose following the development of hypotension during anesthesia.</paragraph>
               </text>
               <effectiveTime value="20170127"/>
            </section>
         </component>
         <component>
            <section ID="LINK_41e52bc8-d10d-4ee3-975d-4a2953a2c10f">
               <id root="a0e6b2d1-ef44-4982-a9ed-2a497c336fa0"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED</title>
               <text>
                  <paragraph>CORPHEDRA (ephedrine sulfate injection), 50 mg/mL, is supplied as follows:</paragraph>
                  <table border="0" cellspacing="0" cellpadding="0">
                     <col width="109.2pt"/>
                     <col width="102.35pt"/>
                     <col width="244.15pt"/>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">NDC</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">S</content>
                                 <content styleCode="bold">tre</content>
                                 <content styleCode="bold">n</content>
                                 <content styleCode="bold">gth</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How Supplied</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>42023-196-01 </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>50 mg/mL</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>1 mL clear glass vial; for single use (supplied in packages of 25)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>42023-233-01 </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>500 mg/10 mL </paragraph>
                              <paragraph>(50 mg/mL)</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>10 mL clear glass vial; multi-dose </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Vial stoppers are not manufactured with natural rubber latex. </paragraph>
                  <paragraph>Store CORPHEDRA, 50 mg/mL, at 20° to 25°C (68° to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature.]  Protect from light. Store in carton until time of use. For single use only. Discard unused portion.</paragraph>
               </text>
               <effectiveTime value="20181017"/>
            </section>
         </component>
         <component>
            <section ID="LINK_5f95a5bc-75bf-4130-8bac-55d1e20dab47">
               <id root="3006b06b-095e-46b8-8555-5b8878406d86"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>Par Pharmaceutical</paragraph>
                  <paragraph>Chestnut Ridge, NY 10977</paragraph>
                  <paragraph>CORPHEDRA is a trademark of Par Pharmaceutical.                                                   </paragraph>
                  <paragraph>R1/17</paragraph>
               </text>
               <effectiveTime value="20170127"/>
            </section>
         </component>
         <component>
            <section ID="LINK_440db6b1-ec12-44e0-af33-2063c69a8c00">
               <id root="ac2557e5-4884-4c77-a4d4-5c517515e367"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel - Vial Label</title>
               <text>
                  <paragraph>NDC 42023-196-01</paragraph>
                  <paragraph>CORPHEDRA (ephedrine Sulfate Injection, USP)</paragraph>
                  <paragraph>50 mg/mL, 1 mL Single-Dose Vial</paragraph>
                  <renderMultiMedia referencedObject="MM2">
                     <caption>Image 2</caption>
                  </renderMultiMedia>
                  <paragraph>NDC 42023-233-01</paragraph>
                  <paragraph>CORPHEDRA (ephedrine Sulfate Injection, USP)</paragraph>
                  <paragraph>500 mg/10 mL, 10 mL Multiple-Dose Vial</paragraph>
                  <renderMultiMedia referencedObject="MM3">
                     <caption>image 3</caption>
                  </renderMultiMedia>
               </text>
               <effectiveTime value="20181017"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Corphedra 50 mg/mL vial label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Corphedra 500 mg/10 mL vial label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>